These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37251396)

  • 1. Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development.
    Sauna ZE; Jawa V; Balu-Iyer S; Chirmule N
    Front Immunol; 2023; 14():1151888. PubMed ID: 37251396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.
    Jawa V; Terry F; Gokemeijer J; Mitra-Kaushik S; Roberts BJ; Tourdot S; De Groot AS
    Front Immunol; 2020; 11():1301. PubMed ID: 32695107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives.
    Di Ianni A; Barbero L; Fraone T; Cowan K; Sirtori FR
    J Pharm Biomed Anal; 2023 Sep; 234():115500. PubMed ID: 37311374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.
    Lotz GP; Benstein K; Bloem K; Buddiger H; Calonder C; Elm S; Fernandez E; Goodman J; Gorovits B; Grudzinska-Goebel J; Janssen M; Jawa V; Kramer D; Luo L; Malisauskas M; Michaut L; Schäfer M; Spindeldreher S; Ullmann M; Nana Weldingh K; Kromminga A; Snoeck V
    AAPS J; 2022 May; 24(3):68. PubMed ID: 35554731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.
    Swanson MD; Rios S; Mittal S; Soder G; Jawa V
    Front Immunol; 2022; 13():915412. PubMed ID: 35967308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (
    Loo L; Harris S; Milton M; Meena ; Lembke W; Berisha F; Bertholet S; Dessy F; Dodge R; Fang X; Fiscella M; Garofolo F; Gorovits B; Gupta S; Jawa V; Ishii-Watabe A; Long B; Lu Y; Mack T; McGuire K; Nolan K; Pan L; Potthoff B; Purushothama S; Smith D; Solstad T; Sonderegger I; Taddeo F; Tangri S; Wagner L; Wu B; Xu Y; Kirshner S; Verthelyi D; Yan H; Maxfield K; Pedras-Vasconcelos J; Abhari MR; Gupta S; Wu Y; Rajadhyaksha M; Andisik M; Baltrukonis D; Cherry E; Cludts I; Gunn G; Millner AH; Jordan G; Kar S; Kubiak R; Lotz GP; Palmer R; Peng K; Poetzl J; Richards S; Savoie N; Staack RF; Stubenrauch K; Wadhwa M; Waxenecker G; Yang TY; Zhang L
    Bioanalysis; 2022 Jun; 14(11):737-793. PubMed ID: 35578991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
    Karle A; Spindeldreher S; Kolbinger F
    MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Product and Process Related Critical Quality Attributes on Immunogenicity and Adverse Immunological Effects of Biotherapeutics.
    Wen Y; Jawa V
    J Pharm Sci; 2021 Mar; 110(3):1025-1041. PubMed ID: 33316242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies.
    Johnson DE
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
    Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A
    AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.
    Vugmeyster Y; Harrold J; Xu X
    AAPS J; 2012 Dec; 14(4):714-27. PubMed ID: 22798020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics.
    Jawa V; Joubert MK; Zhang Q; Deshpande M; Hapuarachchi S; Hall MP; Flynn GC
    AAPS J; 2016 Nov; 18(6):1439-1452. PubMed ID: 27450229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of biotherapeutics-an overview.
    Subramanyam M
    J Immunotoxicol; 2006 Sep; 3(3):151-6. PubMed ID: 18958695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?
    Hassanein M; Partridge MA; Shao W; Torri A
    Bioanalysis; 2020 Sep; 12(18):1325-1336. PubMed ID: 32946271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a FRET-Based Assay for Analysis of mAbs Internalization and Processing by Dendritic Cells in Preclinical Immunogenicity Risk Assessment.
    Wen Y; Cahya S; Zeng W; Lin J; Wang X; Liu L; Malherbe L; Siegel R; Ferrante A; Kaliyaperumal A
    AAPS J; 2020 Apr; 22(3):68. PubMed ID: 32300899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein aggregation and immunogenicity of biotherapeutics.
    Pham NB; Meng WS
    Int J Pharm; 2020 Jul; 585():119523. PubMed ID: 32531452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.